| Product Code: ETC11530933 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Latvia Companion Diagnostics for Oncology Market Overview |
3.1 Latvia Country Macro Economic Indicators |
3.2 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, 2021 & 2031F |
3.3 Latvia Companion Diagnostics for Oncology Market - Industry Life Cycle |
3.4 Latvia Companion Diagnostics for Oncology Market - Porter's Five Forces |
3.5 Latvia Companion Diagnostics for Oncology Market Revenues & Volume Share, By Diagnostic Type, 2021 & 2031F |
3.6 Latvia Companion Diagnostics for Oncology Market Revenues & Volume Share, By Cancer Type, 2021 & 2031F |
3.7 Latvia Companion Diagnostics for Oncology Market Revenues & Volume Share, By Sample Type, 2021 & 2031F |
3.8 Latvia Companion Diagnostics for Oncology Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 Latvia Companion Diagnostics for Oncology Market Revenues & Volume Share, By Technology, 2021 & 2031F |
4 Latvia Companion Diagnostics for Oncology Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in Latvia |
4.2.2 Rising adoption of personalized medicine in oncology |
4.2.3 Technological advancements in companion diagnostics |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for companion diagnostics |
4.3.2 Limited reimbursement policies for companion diagnostics in Latvia |
5 Latvia Companion Diagnostics for Oncology Market Trends |
6 Latvia Companion Diagnostics for Oncology Market, By Types |
6.1 Latvia Companion Diagnostics for Oncology Market, By Diagnostic Type |
6.1.1 Overview and Analysis |
6.1.2 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Diagnostic Type, 2021 - 2031F |
6.1.3 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Molecular Diagnostics, 2021 - 2031F |
6.1.4 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Immunodiagnostics, 2021 - 2031F |
6.1.5 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Genetic Testing, 2021 - 2031F |
6.1.6 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Imaging-Based Diagnostics, 2021 - 2031F |
6.2 Latvia Companion Diagnostics for Oncology Market, By Cancer Type |
6.2.1 Overview and Analysis |
6.2.2 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Lung Cancer, 2021 - 2031F |
6.2.3 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Breast Cancer, 2021 - 2031F |
6.2.4 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Colorectal Cancer, 2021 - 2031F |
6.2.5 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Prostate Cancer, 2021 - 2031F |
6.3 Latvia Companion Diagnostics for Oncology Market, By Sample Type |
6.3.1 Overview and Analysis |
6.3.2 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Blood, 2021 - 2031F |
6.3.3 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Tissue, 2021 - 2031F |
6.3.4 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Saliva, 2021 - 2031F |
6.3.5 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Urine, 2021 - 2031F |
6.4 Latvia Companion Diagnostics for Oncology Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Hospitals, 2021 - 2031F |
6.4.3 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Diagnostic Centers, 2021 - 2031F |
6.4.4 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Research Labs, 2021 - 2031F |
6.4.5 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Pharmaceuticals, 2021 - 2031F |
6.5 Latvia Companion Diagnostics for Oncology Market, By Technology |
6.5.1 Overview and Analysis |
6.5.2 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By PCR-Based, 2021 - 2031F |
6.5.3 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By ELISA, 2021 - 2031F |
6.5.4 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By Microfluidics, 2021 - 2031F |
6.5.5 Latvia Companion Diagnostics for Oncology Market Revenues & Volume, By AI-Based Analysis, 2021 - 2031F |
7 Latvia Companion Diagnostics for Oncology Market Import-Export Trade Statistics |
7.1 Latvia Companion Diagnostics for Oncology Market Export to Major Countries |
7.2 Latvia Companion Diagnostics for Oncology Market Imports from Major Countries |
8 Latvia Companion Diagnostics for Oncology Market Key Performance Indicators |
8.1 Number of new companion diagnostic tests introduced in the market |
8.2 Adoption rate of companion diagnostics by healthcare providers |
8.3 Investment in research and development for companion diagnostics in Latvia |
9 Latvia Companion Diagnostics for Oncology Market - Opportunity Assessment |
9.1 Latvia Companion Diagnostics for Oncology Market Opportunity Assessment, By Diagnostic Type, 2021 & 2031F |
9.2 Latvia Companion Diagnostics for Oncology Market Opportunity Assessment, By Cancer Type, 2021 & 2031F |
9.3 Latvia Companion Diagnostics for Oncology Market Opportunity Assessment, By Sample Type, 2021 & 2031F |
9.4 Latvia Companion Diagnostics for Oncology Market Opportunity Assessment, By End User, 2021 & 2031F |
9.5 Latvia Companion Diagnostics for Oncology Market Opportunity Assessment, By Technology, 2021 & 2031F |
10 Latvia Companion Diagnostics for Oncology Market - Competitive Landscape |
10.1 Latvia Companion Diagnostics for Oncology Market Revenue Share, By Companies, 2024 |
10.2 Latvia Companion Diagnostics for Oncology Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here